Pharmafile.com’s weekly COVID-19 news round-up
Developments in treatments for COVID-19 continue to dominate the news as the latest in hydroxychloroquine trials shows it does not help treat the coronavirus, while South Korea says the Ebola drug remdesivir may not be suitable for all coronavirus patients.
In other news, scientists in the UK and US have identified hundreds of mutations in the COVID-19 virus while black people are four times more likely to die from COVID-19 than white in England and Wales, a new ONS report shows
1. Latest large hydroxychloroquine study suggests it does not help treat COVID-19 – Published on 11/05/2020
The results of another study into the use of hydroxychloroquine in COVID-19 patients has cast further doubts on its effectiveness in treating the virus.
2. Scientists in the UK and US identify hundreds of mutations in the COVID-19 virus – Published 07/05/2020
Two studies from the UK and US have identified hundreds of mutations in COVID-19, which could cause problems for the development of a vaccine.
3. South Korea says Ebola drug remdesivir may not be suitable for all coronavirus patients – Published 06/05/2020
South Korea says that remdesivir, traditionally used in treating Ebola, may not be effective enough in treating COVID-19 patients.
A recent report from the Office of National Statistics has shown that black people in England and Wales are four times more likely to die from the COVID-19 coronavirus than white people.
5. NIAID announces the launch of second remdesivir trial for COVID-19 patients – Published 11/05/2020
The US National Institute of Allergy and Infectious Diseases (NAID) has announced that it is enrolling COVID-19 patients in hospital to be tested with Gilead Sciences’ remdesivir combined with Eli Lilly and Incyte’s JAK inhibitor Olumiant.
ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an …
As of 31 July 2023, The National Institutes of Health (NIH) launched the first trials …